Literature DB >> 9641657

Chronic hepatitis virus infection in children.

M H Chang1.   

Abstract

Hepatitis B and C viruses (HBV and HCV) are the two main hepatitis viruses causing chronic liver diseases in children. In hyperendemic areas, nearly half of the primary infection in chronic HBV carriers occurs during the perinatal period through the transmission from hepatitis B e antigen (HBeAg)-positive mothers. The other half are from horizontal transmission mainly through intrafamilial spread or injection using unsterilized needles. During the natural course of chronic HBV infection, spontaneous HBeAg/anti-HBe seroconversion occurs very rarely (2% annually) before 3 years of age. After 3 years of age, the HBeAg seroconversion rate increases gradually to 5% per year. Those with mothers who are hepatitis B carriers tend to clear HBeAg slower than those whose mothers are non-carriers. Transplacental HBeAg may cause T cell tolerance in infected children. Universal HBV immunization programmes have been effective in reducing the hepatitis B carrier rate more than 10-fold, and the incidence of hepatocellular carcinoma in children has also been decreased significantly. Hepatitis C virus infection occurs mainly in high-risk children, such as those who received blood products (blood diseases, malignancies, post-open heart surgery etc.), children of HCV-infected mothers, and in hyperendemic areas, from injection using unsterile needles. Mother-to-infant transmission occurs on average in 5% of infants of viraemic mothers. The maternal HCV-RNA titre is the most important factor determining the infectivity. Chronicity developed in 60-80% of HCV-infected children. Although transient or persistent elevation of aminotransferases occurs frequently in chronically HCV-infected children, liver histology showed minimal or mild changes only. The most prevalent genotype of HCV in children is Ib. Screening of the blood products for HCV antibody has markedly reduced the rate of HCV infection in children at risk. However, vaccine development is needed to prevent mother-to-infant transmission and other routes of infections.

Entities:  

Mesh:

Year:  1998        PMID: 9641657     DOI: 10.1111/j.1440-1746.1998.tb00685.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Prevalence of hepatitis C virus infection in a cohort of pregnant women in northern Greece and transmission of HCV from mother to child.

Authors:  M Raptopoulou-Gigi; E Orphanou; T H Lalla; A Lita; A Garifallos
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 3.  Natural history of hepatitis B virus infection: pediatric perspective.

Authors:  Yen-Hsuan Ni
Journal:  J Gastroenterol       Date:  2010-09-02       Impact factor: 7.527

4.  Horizontal transmission of hepatitis B virus in children with chronic hepatitis B.

Authors:  Tumay Doganci; Gulnar Uysal; Tayfun Kir; Arzu Bakirtas; Necdet Kuyucu; Levent Doganci
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

5.  Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph.

Authors:  Nikolaus Becker; Paul Schnitzler; Paolo Boffetta; Paul Brennan; Lenka Foretova; Marc Maynadié; Alexandra Nieters; Anthony Staines; Yolanda Benavente; Pierluigi Cocco; Silvia de Sanjose
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-06       Impact factor: 4.553

Review 6.  Liver disease in pregnancy.

Authors:  Noel M Lee; Carla W Brady
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

7.  Mathematical models of e-antigen mediated immune tolerance and activation following prenatal HBV infection.

Authors:  Stanca M Ciupe; Sarah Hews
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.